Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Boyce Burge who wrote (9)	10/1/1996 7:49:00 PM
From: John Metcalf	of 1494

There have been fears of Cerestat side effects mitigating against emergency room use for head trauma. Memantine has been used in other countries, including Germany, for many years and does not carry this side-effect fear. Dr. Gilla Kaplan of Rockefeller University gave an excellent interview which may still be web-accessible on the mechanism of development of AIDS dementia, the indication NTII is pursuing. NTII has several other assets -- corticotropin-releasing factor and dynorphin A under development, and a very low cash burn rate due to a "virtual company" business model in which they spend the minimum on staffing and housing themselves. Consideration of NTII's other assets perhaps balances the equation that CNSI may have a development lead with Cerestat. However, NTII is only valued at 25% of CNSI's level (9/27 close). NTII had a market cap of $31million; CNSI was at $125!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next